Zobrazeno 1 - 10
of 52
pro vyhledávání: '"G A Novichkova"'
Autor:
D A SHASHELEVA, A A MASCHAN, L N SHELIKHOVA, U N PETROVA, E E KURNIKOVA, O I ILLARIONOVA, E V BOYAKOVA, G A NOVICHKOVA, M A MASCHAN
Publikováno v:
Терапевтический архив, Vol 90, Iss 7, Pp 57-64 (2018)
The main goal is to optimize hematopoietic stem cell transplantation (HSCT) approach among adolescents and young adults with paroxysmal nocturnal hemoglobinuria (PNH) by means of Graft-versus-host disease (GVHD) and post-transplant complications risk
Externí odkaz:
https://doaj.org/article/c5aa744b838d4ea0acb3b3e7f77cb253
Autor:
Y Y DYAKONOVA, O I BYDANOV, A M POPOV, Y V OLSHANSKAYA, E G BOICHENKO, O V ALEYNIKOVA, M A MASCHAN, L N SHELIKHOVA, D V LITVINOV, L A KHACHATRYAN, N I PONOMAREVA, L G FECHINA, G A NOVICHKOVA, E D PASHANOV, A I KARACHUNSKIY
Publikováno v:
Терапевтический архив, Vol 90, Iss 7, Pp 37-50 (2018)
Aim. The analysis of experience of nelarabine use in refractory/relapsed T-cell acute lymphoblastic leukemia (T-ALL) depending on the immunophenotype and the line of therapy. Materials and methods. All the patients with relapsed or refractory T-ALL a
Externí odkaz:
https://doaj.org/article/8277c105b38f465fa2bd4074aac1eb65
Autor:
A I Karachunsky, Yu V Rumyantseva, S N Lagoiko, C Bührer, G Tallen, O V Aleinikova, O I Bydanov, N V Korepanova, L V Baidun, T V Nasedkina, A Von Stackelberg, G A Novichkova, A A Maschan, D V Litvinov, N I Ponomareva, K L Kondratchik, E G Mansurova, L G Fechina, O V Streneva, N B Yudina, G R Sharapova, A V Shamardina, I E Gerbek, A P Shapochnik, A G Rumyantsev, G Henze
Publikováno v:
Терапевтический архив, Vol 87, Iss 7, Pp 41-50 (2015)
Aim. To determine predictors for decision-making on a differential approach to choosing glucocorticosteroids (GCS) for children and adolescents with acute lymphoblastic leukemia (ALL). Subjects and methods. The analysis covered 1064 primary patients
Externí odkaz:
https://doaj.org/article/147f5ec7da0240dfa743df8a897f13a9
Autor:
G A Novichkova, M A Maschan, I P Shipitsyna, Yu V Skvortsova, M I Persiantseva, L L Lebedeva, V O Bobrynina, D D Baidildina, O V Goronkova, G G Solopova, L A Khachatryan, U N Petrova, E V Suntsova, I I Kalinina, V V Sinitsyna, E V Skorobogatova, D N Balashov, Z M Dyshlevaya, L N Shelikhova, E E Kurnikova, P E Trakhtman, A A Maschan
Publikováno v:
Терапевтический архив, Vol 82, Iss 7, Pp 41-47 (2010)
Aim. To analyze the efficiency of transplantation of the bone marrow from a HLA-compatible unrelated donor and continued immunosuppressive therapy (IST) in children with aplastic anemia (AA) unresponsive to 2 courses of IST. Subjects and methods. The
Externí odkaz:
https://doaj.org/article/a539b74b2830479ca8268ed25335826e
Autor:
G. G. Solopova, D. D. Baidildina, L. I. Zharikova, I. I. Kalinina, U. N. Petrova, Ye. V. Suntsova, O. V. Goronkova, L. A. Hachatryan, V. V. Sinitsina, G. A. Novichkova, A. A. Maschan, M. A. Maschan
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 8-15 (2022)
Standard therapy of high risk patients with Langerhans cell histiocytosis (LCH) is associated with essential risk of therapy failure. In the present study results of 2-clorodeoxyadenosine usage as alternative therapy in this group of patients are ana
Externí odkaz:
https://doaj.org/article/aff35ebb6ec14d3cbe54f0f6a680cf5f
Autor:
L. A. Khachatrian, M. A. Maschan, Ye. V. Samochatova, M. M. Schneider, D. D. Baidildina, G. G. Solopova, Ye. V. Suntzova, L. I. Zjarikova, U. N. Petrova, V. V. Sinitsina, G. A. Novichkova, A. A. Maschan
Publikováno v:
Онкогематология, Vol 0, Iss 1-2, Pp 34-38 (2022)
Prognosis of patients with juvenile myelomonocytic leukemia not undergoing allogeneic hematopoietic cells transplantation (SCT) is dismal and not affected by any cytotoxic chemotherapy. Differentiating therapy is an attractive approach in JMML, due t
Externí odkaz:
https://doaj.org/article/fd2660cb6eaf48aa8f9d1014cd95ecab
Autor:
T. V. Shamanskaya, S. R. Varfolomeeva, D. Yu. Kachanov, R. A. Moiseenko, M. V. Teleshova, D. M. Konovalov, V. Yu. Roshchin, A. N. Kazakova, L. V. Zemtsova, A. E. Drui, M. Ya. Yadgarov, G. V. Tereshchenko, A. P. Shcherbakov, Yu. N. Likar, M. N. Sukhov, N. S. Grachev, D. G. Akhaladze, M. A. Maschan, A. V. Nechesnyuk, A. V. Pshonkin, E. E. Kurnikova, E. V. Skorobogatova, L. A. Khachatryan, D. K. Fomin, A. A. Maschan, A. G. Rumyantsev, G. A. Novichkova
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:65-91
Treatment of patients with high-risk neuroblastoma (NB) is a complex challenge, and it is based on response to certain elements of therapy. The development and introduction of new treatment approaches, such as GD2-targeted immunotherapy (IT), leads t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e492e09647cb76f8202913086732e783
https://doi.org/10.24287/1726-1708-2023-22-2-65-91
https://doi.org/10.24287/1726-1708-2023-22-2-65-91
Autor:
L. A. Khachatryan, G. A. Novichkova, M. S. Vasilieva, I. S. Kletskaya, A. P. Scherbakov, A. A. Maschan
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:142-151
Kaposiform lymphangiomatosis (KLA) is an aggressive lymphatic anomaly associated with bone involvement, serositis occurring at various sites, the development of Kasabach–Merritt phenomenon, and frequent infectious complications. The International S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c056b0163e59dbf66526956885430a3
https://doi.org/10.24287/1726-1708-2023-22-2-142-151
https://doi.org/10.24287/1726-1708-2023-22-2-142-151
Autor:
E. V. Mikhailova, O. I. Illarionova, M. A. Maschan, G. A. Novichkova, A. I. Karachunskiy, A. M. Popov
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:175-184
Multicolor flow cytometry is now routinely used in laboratory practice for the minimal residual disease (MRD) monitoring in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Wide application of CD19-directed immunotherapy leads to frequent los
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::781f97d9dbc37d237464f9530f8c8784
https://doi.org/10.24287/1726-1708-2023-22-2-175-184
https://doi.org/10.24287/1726-1708-2023-22-2-175-184
Autor:
D. A. Evstratov, A. D. Shutova, Yu. Yu. Dyakonova, S. A. Radygina, Yu. G. Abugova, L. Kh. Anderzhanova, L. A. Vavilova, D. V. Litvinov, G. A. Novichkova, A. M. Popov, V. V. Fominykh, L. A. Khachatryan, L. N. Shelikhova, N. V. Myakova
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:46-52
Today, treatment results for acute lymphoblastic leukemia (ALL) look encouraging, yet 10–15% patients still end up relapsing. The success of relapse treatment is directly dependent on whether or not a tumor clone has been completely eradicated befo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3207d9eaa90510599657df2ed0d9d46c
https://doi.org/10.24287/1726-1708-2023-22-1-46-52
https://doi.org/10.24287/1726-1708-2023-22-1-46-52